

Amendment to the claims:

Please amend the claims as listed in the following listing of claims, which replaces all prior versions, and listings, of claims in the application:

Listing of the Claims:

1. (currently amended): A method for delivery and retention of an active agent in one or more targeted lymph nodes, comprising:
 - a) injecting into a mammal a first composition comprising a ~~ligand~~ biotin conjugated to a ~~colloidal particle~~ liposome comprising a diameter of less than 500 nm; and
 - b) injecting into said mammal a second composition comprising an ~~anti-ligand~~ avidin, wherein said ~~anti-ligand~~ avidin binds to said ~~ligand~~ biotin, and wherein the active agent is bound to or encapsulated in either said ~~colloidal particle~~ liposome or said ~~anti-ligand~~ avidin, and wherein the ~~anti-ligand~~ avidin aggregates with the ~~colloid-ligand~~ liposome-biotin complex at, or just prior to reaching, the one or more targeted lymph nodes.

Claim 2 (canceled).

3. (currently amended): The method of claim [[2]] 1, wherein the liposome comprises phospholipid.
4. (currently amended): The method of claim [[2]] 1, wherein the liposome comprises cholesterol.
5. (original): The method of claim 3, wherein the phospholipid comprises DPPC or DSPC.

Claims 6-7 (canceled).

8. (currently amended): The method of claim 1, wherein the ~~colloidal particle~~ liposome encapsulates or is bound to the active agent.

9. (previously presented): The method of claim 1, wherein the active agent is chosen from the group consisting of diagnostic agents, therapeutic agents, photoactivated dyes, cytotoxic agents, biological response modifiers, hormone suppressants, prodrugs, dyes for visual detection, radiosensitizers, radioprotectors, DNA, RNA, antigens, radioisotopes and neutron capture isotopes.
10. (original): The method of claim 9, wherein the active agent is chosen from the group consisting of radioisotopes and dyes.
11. (original): The method of claim 9, wherein the active agent is chosen from the group consisting of diagnostic agents and dyes for visual detection.
12. (original): The method of claim 9, wherein the active agent is chosen from the group consisting of photoactivated dyes, cytotoxic agents, biological response modifiers, hormone suppressants, prodrugs, radiosensitizers, radioprotectors, DNA, RNA, and neutron capture agents.
13. (currently amended): The method of claim 1, wherein the ~~anti-ligand~~ avidin is bound to said active agent.

Claim 14 (canceled).

15. (currently amended): A method for detecting one or more sentinel lymph nodes comprising:
 - a) injecting into a mammal a first composition comprising a ~~ligand~~ biotin conjugated to a ~~colloidal particle~~ liposome comprising a diameter of less than 500nm; and
 - b) injecting into said mammal a second composition comprising ~~anti-ligand~~ avidin, wherein said ~~anti-ligand~~ avidin binds to said ~~ligand~~ biotin,

wherein a radioisotope or a dye is bound to or encapsulated in either said ~~colloidal particle~~ liposome or said ~~anti-ligand~~ avidin, and wherein the ~~anti-ligand~~ avidin aggregates with the ~~colloidal-ligand~~ liposome-biotin complex at, or just prior to reaching, the one or more sentinel lymph nodes.

16. (currently amended): The method of claim 15, wherein the ~~colloidal particle~~ liposome encapsulates the radioisotope or dye.
17. (currently amended): The method of claim 16, wherein the ~~colloidal particle~~ liposome encapsulates the radioisotope.
18. (currently amended): The method of claim 15, wherein the ~~anti-ligand~~ avidin is bound to said radioisotope or dye.
19. (currently amended): The method of claim 18, wherein the ~~anti-ligand~~ avidin is bound to said radioisotope.

Claims 20-28 (canceled).

29. (previously presented): The method of claim 9, wherein the active agent comprises a radioisotope and a dye.
30. (previously presented): The method of claim 16, wherein the detection agent comprises a radioisotope and a dye.

Claims 31-32 (canceled).

33. (currently amended): The method of claim 32, wherein the ~~colloidal particle~~ liposome comprises a size range of 50 to 300 nm.

34. (previously presented): The method of claim 1, wherein the first and second compositions are administered by subcutaneous, subdermal, submucosal, intraperitoneal, intrapleural, intraarticular, intramucosal, intramuscular, intradermal, intratumoral, interstitial, intraorgan, intracavitary, intralymphatic, intralesion, or intraosseal injection.

Claims 35-36 (canceled).

37. (currently amended): The method of claim 36, wherein the ~~colloidal particle~~ liposome comprises a size range of 50 to 300 nm.

38. (previously presented): The method of claim 15, wherein the first and second compositions are administered by subcutaneous, subdermal, submucosal, intraperitoneal, intrapleural, intraarticular, intramucosal, intramuscular, intradermal, intratumoral, interstitial, intraorgan, intracavitary, intralymphatic, intralesion, or intraosseal injection.

Claims 39-40 (canceled).